Not recruiting
Psoriasis
Not recruitingInvestigational
ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis
Investigational
- Disease:Psoriasis
- Substances:–
Countries:
Germany
Germany- Participants:18–64 years · 65+ years
Find therapies in clinical trials near you – page 18
- recruiting
- 3 955
- countries
- 28
- conditions
- 2 101
3 955 trials recruiting28 European countries2 101 conditions coveredUpdated today
434 trials match your criteria
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:–
Countries:Germany
Germany- Participants:18–64 years · 65+ years
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
A Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:–
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
Not recruiting
Migraine
Not recruitingInvestigational
Study of IPN10200 compared to placebo for prevention of episodic or chronic migraine in adults
Investigational
- Disease:Migraine
- Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Clostridium Botulinum, Neurotoxin Serotype A/B
Not recruiting
Psoriasis
Not recruitingRegistered drug
Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis
Registered drug
- Disease:Psoriasis
- Substances:ApremilastZasocitinib
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Apremilast
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Investigational
- Disease:Dermatitis atopic
- Substances:Rocatinlimab
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Rocatinlimab
Not recruiting
Hidradenitis
Not recruitingInvestigationalNo placebo
Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa
InvestigationalNo placebo
- Disease:Hidradenitis
- Substances:Sonelokimab
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Sonelokimab
Not recruiting
Hypercholesterolaemia
Not recruitingInvestigational
Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels
Investigational
- Disease:Hypercholesterolaemia
- Substances:–
Countries:Germany
Germany- Participants:18–64 years · 65+ years
Not recruiting
Dermatitis atopic
Not recruitingInvestigational
Study of Ruxolitinib Cream for Children and Adolescents Ages 6-17 with Moderate Atopic Dermatitis Who Did Not Respond Well to Standard Treatments
Investigational
- Disease:Dermatitis atopic
- Substances:Ruxolitinib
Countries:Germany
Germany- Participants:0–17 years
- Substances:Ruxolitinib
Not recruiting
Neuralgia+1
Not recruitingInvestigational
Study on LY3848575 for Reducing Pain in Patients with Distal Sensory Polyneuropathy
Investigational
- Disease:NeuralgiaPolyneuropathy
- Substances:LY3848575
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:LY3848575
Not recruiting
Psoriasis
Not recruitingRegistered drug
Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis
Registered drug
- Disease:Psoriasis
- Substances:Jnj-77242113Ustekinumab
Countries:Germany
Germany- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Jnj-77242113
Not recruiting
Psoriasis
Not recruitingInvestigational
Study on Long-term Safety and Effectiveness of ESK-001 for Patients with Moderate to Severe Plaque Psoriasis
Investigational
- Disease:Psoriasis
- Substances:Envudeucitinib
Countries:Germany
Germany- Participants:18–64 years · 65+ years
- Substances:Envudeucitinib